Problem

Everlab addresses the fragmentation and reactive nature of conventional healthcare. Patients often move between providers whose records do not connect, transactional telehealth services that lack continuity, and wearables that generate data without enough clinical interpretation. The result is a limited view of health, missed risk signals, and delayed action. Everlab’s economic thesis is that preventive care can improve outcomes and, in some cases, reduce total healthcare costs, while technology can make personalised, data-driven care more affordable than the traditionally bespoke services available mainly to wealthy patients.

The killer use case is a proactive health baseline for an individual or corporate executive cohort: consolidate past records, assess future risk, use advanced diagnostics to identify problems before symptoms appear, and coordinate the next clinical steps. The company particularly targets hidden metabolic, cardiovascular, cancer, genetic and ageing-related risks, turning an otherwise fragmented set of tests and appointments into an actionable prevention plan.

Product / Service

Everlab is an AI-enabled preventive-health and longevity service delivered through a tiered membership and diagnostics model. Customers begin with a $299 baseline deposit, submit historical medical records, and meet a longevity doctor who defines their risks, priorities and goals. The doctor then recommends a tailored set of tests and interventions, which can include advanced bloodwork, DEXA, genetic and methylation testing, whole-body MRI, cardiac CT, skin checks and gut-microbiome analysis. Results are reviewed by clinicians—whole-body scans, for example, receive radiologist and specialty-GP review—before being converted into a personalised action plan.

The app provides the operating layer: it organises diagnostics, medical records, doctors, specialists, prescriptions, wearable data and AI-supported insights in one longitudinal view. Members can book tests, receive clinician guidance, track biomarkers, habits and goals, and repeat assessments at recommended milestones. Everlab uses a broad external network rather than needing to own every scanner or clinic, combining clinical coordination with ongoing digital support and the potential benefit of earlier, more targeted intervention.

Market

Everlab competes in preventive healthcare, longevity medicine and AI-enabled consumer healthtech. Its comparison set includes integrated-checkup provider Neko Health; laboratory-led memberships such as Function Health and Superpower; whole-body-MRI specialist Prenuvo; and premium longevity platforms including Fountain Life, Biograph and Q Bio. Everlab’s distinctive position is as a coordination layer across diagnostics and follow-up: its network connects more than 1,850 provider locations, 180 active clinicians and over 30 wearable devices, rather than relying solely on a proprietary clinic or a single test.

The company is commercially active rather than pre-revenue, although revenue figures were not disclosed in the available evidence. Founded in Melbourne in 2023, Everlab operates across Australia and New Zealand and announced an AU$65 million Series A in June 2026 to expand internationally, beginning with the UK. It reports more than 40,000 consultations for 20,000 individual patients, corporate customers including Boston Consulting Group, BHP and Bain & Company, and more than 200,000 health reports processed monthly—traction that provides a meaningful base for its consumer and employer-led expansion.